Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548207 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT03548207 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 126 participants.
The verdict
NCT03548207, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
Interventions
- BIOLOGICAL JNJ-68284528
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03548207
The ClinicalTrials.gov registry entry for NCT03548207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-68284528 is the first listed.
NCT03548207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03548207 about?
NCT03548207 is a clinical study titled "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
What is the current status of trial NCT03548207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2018-06-29. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT03548207?
The interventions under investigation include: JNJ-68284528 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03548207?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.